The Glucose Never Lies® Podcast

John Pemberton
  • 3.7 (3)
  • FITNESS
  • UPDATED WEEKLY

Host John Pemberton — diabetes educator, researcher, and dad living with type 1 since 2008 — explores how to think clearly about type 1 diabetes in the real world. Each episode translates current evidence and expert practice into decisions you can use: CGM accuracy and interpretation, getting more from pumps and automated insulin delivery, movement as a glucose tool, nutrition that protects performance and enjoyment, sleep, travel, parties, and sport. Guests include leading clinicians, researchers, and people with lived experience. Expect respectful challenge, plain language, and practical take-aways. Note: Educational only. No therapeutic relationship or personal medical advice. Buy the GNL a Coffee to keep us independent:  https://www.buymeacoffee.com/jspfree2s Email: john@theglucoseneverlies.com 

  1. Episode 39: Abbott FreeStyle Libre - Accuracy, Simplicity and What's Next

    APR 27

    Episode 39: Abbott FreeStyle Libre - Accuracy, Simplicity and What's Next

    Suggest guests or get in contact Michael Skarlatos from Abbott UK Medical Affairs joins John Pemberton for the second manufacturer episode of the CGM Series. A former diabetes specialist dietitian at University Hospitals of Leicester, Michael brings real clinical experience to an honest breakdown of the FreeStyle Libre 2 Plus and 3 Plus. This episode covers: - Why Abbott accuracy data qualifies these sensors for insulin dosing: ICGM approved, 20/20 performance ~95-96%, outside-40/40 error rate 0.2% - What 70% smaller means in practice: form factor, stigma, and the all-in-one applicator on Libre 3 Plus - Pump integrations now and the roadmap: CamAPS FX, Omnipod 5, and what is coming - Libreview: why Abbott moved off Glooko and what population health management enables - Libreview Pro in SystmOne and EMIS with SNOMED-coded CGM metrics - A critical data nuance: glucose measured every minute on the patient app but recorded every 5 minutes in clinical downloads - Continuous ketone monitoring: what Abbott has in development and who benefits most CHAPTERS 00:00 Introduction and CGM Series overview 00:57 Michaels background and Leicester NHS Trust 02:25 Moving from NHS to Abbott Medical Affairs 03:27 Accuracy credentials: ICGM approval and 20/20 performance 05:44 FreeStyle Libre 3 Plus: size and form factor 09:25 Pump integrations: CamAPS FX, Omnipod 5, and the roadmap 10:19 ICGM interoperability: US vs CE marking in Europe 12:05 Fifteen-day wear period 12:28 Abbott market history: free samples and patient-led adoption 14:04 Simplicity of onboarding and multi-language support 16:58 Starter clinics: taking onboarding off the HCP 19:33 Libreview and population health management 23:21 EHR integration, SNOMED codes, and QOF implications 25:46 Practical tips: Bluetooth connectivity and the app cache 29:23 Minute-by-minute data vs five-minute trend recording 30:58 Low glucose event thresholds and hypo underreporting 31:42 Continuous ketone monitoring: what is coming from Abbott 37:52 CGM beyond type 1 and patient advocacy 40:17 Closing thoughts LINKS Show notes: https://theglucoseneverlies.com/episode-38-freestyle-libre-abbott/ YouTube: https://youtu.be/IW1sa5APHU8 CGM Series: https://theglucoseneverlies.com/10-13-cgm-series/ GNL Explorers: https://theglucoseneverli Disclaimer This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care. The Glucose Never Lies® is independent by design We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider: Buying the GNL a Coffee: https://www.buymeacoffee.com/jspfree2 Enquiries Collaboration: John Pemberton — john@theglucoseneverlies.com Creatives: Anjanee Kohli — anj@theglucoseneverlies.com Follow The Glucose Never Lies® Website: https://theglucoseneverlies.com/ Instagram: https://www.instagram.com/theglucoseneverlies LinkedIn: https://www.linkedin.com/company/theglucoseneverlies LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/ X: https://twitter.com/GlucoseNLies Disclaimer This content is for informational purposes only and does not constitute medical advice. © The Glucose Never Lies Ltd. All rights reserved.

    42 min
  2. Episode 38: Q1 2026 Quarterly Review, GNL Grace, the Explorers, and What Changed

    APR 20

    Episode 38: Q1 2026 Quarterly Review, GNL Grace, the Explorers, and What Changed

    Suggest guests or get in contact Three months ago, GNL was a website full of excellent content that was genuinely hard to find. In Episode 38, John Pemberton and Creative Director Anjanee Kohli talk through what happened next: a complete website rebuild, five interactive explorers, the launch of GNL Grace, real-world validation on 1.5 million patient days, and what the Robin Hood model of type 1 diabetes education actually means. In this episode: CGM guide update and the five-out-of-five accuracy chartHow the five GNL Explorers work and how clinicians are using them in practiceGNL Grace: a bounded AI educational advisor built on 2,000 curated citationsThree Grace tiers: Basic (free), Pro (30 queries/month for subscribers), Max (manuscript-grade output)The Robin Hood model: industry grants fund free education for everyoneReal-world validation: 33 assessments on 1.5 million patient daysWhy the skill of the future in healthcare is compassion, not knowledgePhil Hayes joining as Technical DirectorGNL merch and the Diabetes UK giveawayChapters: 00:00 Introduction01:55 GNL Grace announcement02:32 CGM guide and accuracy chart05:30 Phil Hayes and the explorer infrastructure09:40 GNL Grace: the six-layer bounded AI10:50 Grace tiers and the Robin Hood model13:31 Grace Max: manuscript-grade output17:31 Real-world validation on 1.5 million patient days19:58 The skill of the future is compassion30:09 What went wrong and lessons learned35:06 GNL merch36:10 ClosingLinks: Show notes: theglucoseneverlies.com/episode-38-quarterly-reviewGNL Grace: theglucoseneverlies.com/gnl-graceGNL Explorers: theglucoseneverlies.com/gnl-explorersCGM Series hub: theglucoseneverlies.com/10-13-cgm-seriesHost: John Pemberton. Director of Creativity: Anjanee Kohli. This content is for educational exploration only. It is not medical Disclaimer This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care. The Glucose Never Lies® is independent by design We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider: Buying the GNL a Coffee: https://www.buymeacoffee.com/jspfree2 Enquiries Collaboration: John Pemberton — john@theglucoseneverlies.com Creatives: Anjanee Kohli — anj@theglucoseneverlies.com Follow The Glucose Never Lies® Website: https://theglucoseneverlies.com/ Instagram: https://www.instagram.com/theglucoseneverlies LinkedIn: https://www.linkedin.com/company/theglucoseneverlies LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/ X: https://twitter.com/GlucoseNLies Disclaimer This content is for informational purposes only and does not constitute medical advice. © The Glucose Never Lies Ltd. All rights reserved.

    37 min
  3. Episode 37: Dexcom G7 and ONE+| Adam Dawes | GNL Podcast

    APR 13

    Episode 37: Dexcom G7 and ONE+| Adam Dawes | GNL Podcast

    Suggest guests or get in contact Most people with T1D have switched their CGM high alert off. Not because they do not care - because it goes off every time they eat and there is nothing they can do about it. Episode 37 is about what Dexcom built to fix that. Adam Dawes, Senior Medical Affairs Manager at Dexcom UK and Ireland - and a former paediatric diabetes nurse specialist - joins John Pemberton for the third manufacturer episode of the CGM Series. An honest clinical conversation about the Dexcom G7 and ONE+, what separates them, and where Dexcom is heading next. This episode covers: - Dexcom G7 vs Dexcom ONE+: same hardware platform, different software, and what that means for matching the right sensor to the right patient - Delay 1st Alert: why it is one of the most underused alerts in CGM, how it eliminates alarm fatigue without reducing safety, and how John uses it himself - AID integrations: Tandem T:slim X2, Omnipod 5, mylife, and the Tandem Mobi - CGM for type 2 diabetes: the biofeedback argument and why immediate glucose feedback changes behaviour in ways a quarterly HbA1c never can - The Dexcom roadmap from ATTD 2026: 15-day sensor, Dexcom G8 next generation sensor, EPIC integration, Clarity updates, and generative AI - Why insulin dosing will never be a commodity market - and what people with T1D need to understand as new CGMs enter the UK - The FDA manufacturing findings: what happened, how Dexcom responded, and why the new Ireland factory matters Show notes: https://theglucoseneverlies.com/episode-37-dexcom-g7-one-plus/ | CGM Series: https://theglucoseneverlies.com/10-13-cgm-series/ Have more questions about CGM, the Dexcom G7 or ONE+? Ask GNL Grace: https://theglucoseneverlies.com/gnl-grace/ Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00 The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08. Disclaimer This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care. The Glucose Never Lies® is independent by design We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider: Buying the GNL a Coffee: https://www.buymeacoffee.com/jspfree2 Enquiries Collaboration: John Pemberton — john@theglucoseneverlies.com Creatives: Anjanee Kohli — anj@theglucoseneverlies.com Follow The Glucose Never Lies® Website: https://theglucoseneverlies.com/ Instagram: https://www.instagram.com/theglucoseneverlies LinkedIn: https://www.linkedin.com/company/theglucoseneverlies LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/ X: https://twitter.com/GlucoseNLies Disclaimer This content is for informational purposes only and does not constitute medical advice. © The Glucose Never Lies Ltd. All rights reserved.

    54 min
  4. 36: CGM Series - CGM Accuracy, DSN Reality Checks and the Future of Diabetes Technology

    MAR 29

    36: CGM Series - CGM Accuracy, DSN Reality Checks and the Future of Diabetes Technology

    Suggest guests or get in contact CGM Series | The Glucose Never Lies® Podcast Three of the UK's leading diabetes specialist nurses on why CE marking is not a quality standard for CGM accuracy, why data sufficiency must come before device comparison, and what ATTD 2025 revealed about where diabetes technology is heading. A frank, clinical conversation grounded in years of front-line practice — and the story of how the DSN Forum's five-point accuracy scoring system was built. In this episode: Why the DSN Forum created its CGM comparison chart and how it has evolvedWhy CE marking is not a quality standard for CGM accuracyHow the five-point accuracy scoring system works and what it requires from a deviceWhy only four devices currently meet the data sufficiency standardWhat 20/20 and 40/40 agreement rates mean in real clinical termsWhy everyone using CGM for insulin decisions still needs a working finger-prick meterThe calibration debate: does the option to calibrate add safety or risk?What ATTD 2025 revealed about fully closed loop systems — and who may not benefitThe case for GLP-1 in type 1 diabetes and why priority access mattersAbbott's continuous ketone monitor: opportunity, unknowns, and risksAID system optimisation, insulin on board, and the GNL AID System ExplorerChapters: 00:00 — Introduction: meeting Amanda, Beth and Tamsin02:14 — Why the DSN Forum CGM comparison chart was created06:47 — Turning complex CGM evidence into a practical scoring system16:23 — How CGM choice works in real clinical settings20:36 — Why finger-prick testing still matters — and the calibration debate29:26 — What stood out at ATTD 202544:03 — AID systems, insulin on board, and the GNL AID optimiser49:49 — Where to find the DSN Forum, the chart, and closing thoughtsGuests: Amanda Williams (Lead Diabetes Nurse, East Kent), Beth Kelly (Clinical Lead DSN, Wiltshire), Tamsin Fletcher-Salt (Lead DSN, University Hospital North Midlands). All core members of the Diabetes Specialist Nurse Forum UK. Links: Full show notes: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/DSN Forum CGM Comparison Chart: https://www.diabetesspecialistnDisclaimer This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care. The Glucose Never Lies® is independent by design We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider: Buying the GNL a Coffee: https://www.buymeacoffee.com/jspfree2 Enquiries Collaboration: John Pemberton — john@theglucoseneverlies.com Creatives: Anjanee Kohli — anj@theglucoseneverlies.com Follow The Glucose Never Lies® Website: https://theglucoseneverlies.com/ Instagram: https://www.instagram.com/theglucoseneverlies LinkedIn: https://www.linkedin.com/company/theglucoseneverlies LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/ X: https://twitter.com/GlucoseNLies Disclaimer This content is for informational purposes only and does not constitute medical advice. © The Glucose Never Lies Ltd. All rights reserved.

    51 min
  5. 35: CGM Series - The Importance of CGM Accuracy and Study Design with Professor Othmar Moser

    MAR 23

    35: CGM Series - The Importance of CGM Accuracy and Study Design with Professor Othmar Moser

    Suggest guests or get in contact CGM Series | The Glucose Never Lies® Podcast CGM accuracy is usually described with a single number: MARD. But a low MARD can hide significant risk if the study behind it was poorly designed. Professor Othmar Moser — one of the leading independent CGM accuracy researchers — explains what study design actually determines, why meal and insulin challenges are non-negotiable, and what people with type 1 diabetes and clinicians should look for when evaluating any accuracy claim. In this episode: What MARD is and why it misleads when used in isolationThe five study design questions that determine what accuracy data actually meansWhy 20/20 and 40/40 agreement rates reveal what MARD cannotWhy meal and insulin challenges are essential for real-world accuracy testingWhat CE marking does and does not guarantee about CGM performanceWhy peer-reviewed, independent evidence is the gold standard — and how little of what is cited meets itHow study design quality shapes what we actually know about CGM riskProfessor Moser's perspective as a researcher who designs and runs these studiesGuest: Professor Othmar Moser, Medical University of Graz, Austria. Leading figure in independent CGM accuracy study design and insulin-related exercise physiology research in type 1 diabetes. Links: Full show notes: https://theglucoseneverlies.com/episode-35-cgm-series-the-importance-of-cgm-accuracy-and-study-design-with-professor-othmar-moser/CGM Guide Part 2 — Assessing CGM Accuracy: https://theglucoseneverlies.com/assessing-cgm-accuracy-performance/CGM Guide Part 1 — How to Choose a CGM: https://theglucoseneverlies.com/select-continuous-glucose-monitor-cgm-understanding/Episode 36 — DSN Forum: CGM Accuracy and ATTD 2025: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/Watch on YouTube: https://youtu.be/zTdTps42kQ8Educational purposes only. Not medical advice. Always work with your diabetes care team. Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00 The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08. Disclaimer This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care. The Glucose Never Lies® is independent by design We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider: Buying the GNL a Coffee: https://www.buymeacoffee.com/jspfree2 Enquiries Collaboration: John Pemberton — john@theglucoseneverlies.com Creatives: Anjanee Kohli — anj@theglucoseneverlies.com Follow The Glucose Never Lies® Website: https://theglucoseneverlies.com/ Instagram: https://www.instagram.com/theglucoseneverlies LinkedIn: https://www.linkedin.com/company/theglucoseneverlies LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/ X: https://twitter.com/GlucoseNLies Disclaimer This content is for informational purposes only and does not constitute medical advice. © The Glucose Never Lies Ltd. All rights reserved.

    1 hr
  6. 34 — Building High-Performance Type 1 Diabetes Care: Technology, Targets, and Equity (Dr Peter Adolfsson)

    MAR 4

    34 — Building High-Performance Type 1 Diabetes Care: Technology, Targets, and Equity (Dr Peter Adolfsson)

    Suggest guests or get in contact How do some countries consistently achieve lower HbA1c and better outcomes in type 1 diabetes while others struggle — even with the same technologies? In this episode, John Pemberton speaks with Dr Peter Adolfsson, paediatric diabetologist in Sweden and lead author of the ISPAD 2022 Exercise Guidelines, about what actually drives population-level improvements in type 1 diabetes care. Full show notes: https://theglucoseneverlies.com/episode-34-building-high-performance-type-1-diabetes-care-technology-targets-and-equity-dr-peter-adolfsson/ KEY TOPICS • How Sweden’s national diabetes registry drives accountability and rapid improvement  • Why structured onboarding and early follow-up are essential for CGM and AID success  • The role of national collaboration between clinics to share best practice  • Why the highest HbA1c group should often be first in line for AID systems  • Moving toward time in tight range (3.9–7.8 mmol/L) as the next clinical target • Equity in diabetes technology: checking subconscious bias with real data • Why celebrating small improvements builds long-term engagement WHAT YOU’LL LEARN ✓ Why early investment in education and follow-up changes long-term outcomes  ✓ How national benchmarking between clinics improves diabetes care  ✓ Why targets matter — changing what you measure changes what improves  ✓ How to use AID systems strategically for people struggling with bolusing  ✓ Why the first two years after diagnosis are a critical window for glycaemic outcomes  ✓ The importance of psychology, social support, and multidisciplinary teams FUTURE OF TYPE 1 DIABETES CARE • AI-supported platforms that analyse CGM data continuously  • Clinics responding earlier when glucose control deteriorates  • Personalised therapy combining insulin with adjunct treatments (e.g., GLP-1RA)  • More flexible care models where stable patients may need fewer clinic visits Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00 The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08. Disclaimer This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care. The Glucose Never Lies® is independent by design We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider: Buying the GNL a Coffee: https://www.buymeacoffee.com/jspfree2 Enquiries Collaboration: John Pemberton — john@theglucoseneverlies.com Creatives: Anjanee Kohli — anj@theglucoseneverlies.com Follow The Glucose Never Lies® Website: https://theglucoseneverlies.com/ Instagram: https://www.instagram.com/theglucoseneverlies LinkedIn: https://www.linkedin.com/company/theglucoseneverlies LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/ X: https://twitter.com/GlucoseNLies Disclaimer This content is for informational purposes only and does not constitute medical advice. © The Glucose Never Lies Ltd. All rights reserved.

    51 min
  7. 33 — Exercise Evidence for Females with T1D: Mind the Gap | Associate Professor Jane Yardley

    FEB 11

    33 — Exercise Evidence for Females with T1D: Mind the Gap | Associate Professor Jane Yardley

    Suggest guests or get in contact Exercise guidelines for type 1 diabetes are built on research dominated by male participants. Professor Jane Yardley, a leading exercise physiologist, bridges the research gap between male and female exercise physiology in type 1 diabetes. This conversation reveals why carbohydrate recommendations systematically overestimate female needs, how menstrual cycle phases alter insulin requirements during exercise, why peripheral hyperinsulinemia creates unique barriers to fat loss, and how fasted morning exercise offers a low-risk, high-reward strategy for improving insulin sensitivity and accessing fat stores. Full show notes: https://theglucoseneverlies.com/females-exercise-t1d/ KEY TOPICS: • Why ~60-70% of females experience luteal phase insulin resistance (10-50% increased needs) • How AID systems struggle to keep up with rapid menstrual cycle changes • Why per-kilogram carb recommendations overestimate female athletes' needs • The peripheral hyperinsulinemia barrier: 4-8× higher insulin blocks fat release • Fasted exercise: zero planning, minimal hypo risk, maximum fat burning • Why muscle and bone health in your 20s-30s determines mobility in your 60s-80s • Menopause transitions and accelerated cardiovascular risk WHAT YOU'LL LEARN: ✓ Luteal phase exercise may require larger insulin adjustments ✓ Females use more fat as fuel — estrogen promotes fat oxidation ✓ Bolus insulin lasts 6 hours, not 2-4 (why "between meals" isn't truly fasted) ✓ Morning fasted exercise depletes glycogen and improves all-day insulin sensitivity ✓ How to overcome the fat loss barrier created by high peripheral insulin ✓ Why resistance training NOW prevents fractures and disability later ✓ Pregnancy exercise principles (sparse data, clear physiology) PRACTICAL STRATEGIES: → Fasted morning exercise: roll out of bed, black coffee, go — no adjustments needed → Luteal phase: consider 60-70% basal cuts (not 50%) for postprandial exercise → Start with LESS carbohydrate than guidelines suggest, adjust based on YOUR response → Build peak muscle/bone by age 30 — you can't make up for lost time at retirement → Post-meal walks in pregnancy: 15-20 min keeps glucose 7.8 mmol/L without extra insulin GUE Disclaimer This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care. The Glucose Never Lies® is independent by design We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider: Buying the GNL a Coffee: https://www.buymeacoffee.com/jspfree2 Enquiries Collaboration: John Pemberton — john@theglucoseneverlies.com Creatives: Anjanee Kohli — anj@theglucoseneverlies.com Follow The Glucose Never Lies® Website: https://theglucoseneverlies.com/ Instagram: https://www.instagram.com/theglucoseneverlies LinkedIn: https://www.linkedin.com/company/theglucoseneverlies LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/ X: https://twitter.com/GlucoseNLies Disclaimer This content is for informational purposes only and does not constitute medical advice. © The Glucose Never Lies Ltd. All rights reserved.

    1h 12m
  8. 32 — Menstrual Cycles & Type 1 Diabetes: The Gender Gap in Care | Dr. Cecilia Nobili

    FEB 9

    32 — Menstrual Cycles & Type 1 Diabetes: The Gender Gap in Care | Dr. Cecilia Nobili

    Suggest guests or get in contact The menstrual cycle affects half of people with type 1 diabetes, yet it's nearly invisible in clinical guidelines, research, and technology design. Dr. Cecilia Nobili — a pediatric diabetology resident and researcher living with T1D — bridges the gap between lived experience and clinical evidence. In this episode, Dr. Nobili shares findings from her observational study of 170 women, revealing how different insulin delivery systems handle monthly hormonal shifts, which phases create the biggest burden, and why this represents a genuine gender gap in diabetes care. Full show notes: https://theglucoseneverlies.com/menstrual-cycle-t1d/  KEY TOPICS: • Why 60% of women on MDI experience ≥5% drop in time in range during luteal phase • How AID systems cut glucose deterioration in half — but aren't perfect • Why hypoglycemia when bleeding starts is often more burdensome than luteal phase highs • Practical strategies for each AID system (780G, Omnipod 5, Control-IQ, CamAPS FX) and MDI • The progesterone effect: why insulin resistance peaks before your period • How to anticipate changes and adjust proactively rather than reactively • Why this should be built into algorithms (but isn't) WHAT YOU'LL LEARN: ✓ The five phases of the menstrual cycle and their glucose impact ✓ Which AID systems show the most stability across cycle phases ✓ Target adjustments, boost functions, and profile switches that actually work ✓ Why pre-bolusing matters more during the luteal phase ✓ How to prevent the hypoglycemia tsunami when bleeding starts ✓ Why one bad day per month is not catastrophic Dr. Nobili's research is funded by a grant and represents the first multi-center study specifically examining menstrual cycle glucose patterns across insulin delivery modalities. This episode provides the structured guidance that should exist in every diabetes clinic — but doesn't. GUEST: Dr. Cecilia Nobili Pediatric Diabetology Resident, Turin, Italy Living with T1D  Multi-center researcher on menstrual cycles and glucose control Full show notes, practical checklists, and related episodes: https://theglucoseneverlies.com/menstrual-cycle-t1d/  Support GNL: https://buy.stripe.com/9B63cx4UO3KEdK Disclaimer This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care. The Glucose Never Lies® is independent by design We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider: Buying the GNL a Coffee: https://www.buymeacoffee.com/jspfree2 Enquiries Collaboration: John Pemberton — john@theglucoseneverlies.com Creatives: Anjanee Kohli — anj@theglucoseneverlies.com Follow The Glucose Never Lies® Website: https://theglucoseneverlies.com/ Instagram: https://www.instagram.com/theglucoseneverlies LinkedIn: https://www.linkedin.com/company/theglucoseneverlies LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/ X: https://twitter.com/GlucoseNLies Disclaimer This content is for informational purposes only and does not constitute medical advice. © The Glucose Never Lies Ltd. All rights reserved.

    55 min
See All (40)

Trailer

Ratings & Reviews

3.7
out of 5
3 Ratings

About

Host John Pemberton — diabetes educator, researcher, and dad living with type 1 since 2008 — explores how to think clearly about type 1 diabetes in the real world. Each episode translates current evidence and expert practice into decisions you can use: CGM accuracy and interpretation, getting more from pumps and automated insulin delivery, movement as a glucose tool, nutrition that protects performance and enjoyment, sleep, travel, parties, and sport. Guests include leading clinicians, researchers, and people with lived experience. Expect respectful challenge, plain language, and practical take-aways. Note: Educational only. No therapeutic relationship or personal medical advice. Buy the GNL a Coffee to keep us independent:  https://www.buymeacoffee.com/jspfree2s Email: john@theglucoseneverlies.com 

Information

  • Creator
    John Pemberton
  • Years Active
    2025 - 2026
  • Episodes
    40
  • Rating
    Clean
  • Copyright
    © 2026 The Glucose Never Lies® Podcast
  • Show Website
    The Glucose Never Lies® Podcast

You Might Also Like